Trigger point injection with bupivacaine — Competitive Intelligence Brief

Trigger point injection with bupivacaine (Trigger point injection with bupivacaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain Management.

marketed Local anesthetic Voltage-gated sodium channels Pain Management Small molecule

Target snapshot

Trigger point injection with bupivacaine (Trigger point injection with bupivacaine) — George Washington University. Bupivacaine blocks sodium channels in nerve fibers, interrupting pain signal transmission when injected directly into trigger points.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trigger point injection with bupivacaine TARGET	Trigger point injection with bupivacaine	George Washington University	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine FNB	Bupivacaine FNB	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic	Voltage-gated sodium channels
Regular bupivacaine	Regular bupivacaine	Vanderbilt University Medical Center	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine %0.25 (isobaric)	Bupivacaine %0.25 (isobaric)	Bursa City Hospital	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Standard dose topiramate	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Bupivacain (Postoperative)	Bupivacain (Postoperative)	Başakşehir Çam & Sakura City Hospital	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
LD: Lidocaine and dexamethasone	LD: Lidocaine and dexamethasone	B.P. Koirala Institute of Health Sciences	marketed	Local anesthetic with corticosteroid combination	Voltage-gated sodium channels (lidocaine); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class